Effects of ginsenoside C-K on seizure activity in pilocarpine-induced epileptic rats

Abstract

Abstract:

AIM: To investigate the effects of ginsenoside C-K on behavior in epileptic rats and its synergistic effect with lamotrigine. METHODS: 70 male SD rats were randomly divided into normal group, model group, lamotrigine group, ginsenoside C-K low, middle, high group, lamotrigine and ginsenoside C-K combination group. Rats in model group and treatment group were prepared for epilepsy animal model by intraperitoneal injection of lithium chloride-pilocarpine after administration of lamotrigine or ginsenoside C-K. Behavior changes were closely observed by video monitoring system after pilocarpine. Behavioural seizure activity was scored according to Racine grading standard and recorded seizure latency. RESULTS: After treatment of ginsenoside C-K, the treatment group rats exhibited significant an increase in seizure latency compared with epilepsy model group. The loss of body wieght reduced significantly in these surviving animals pretreated with ginsenoside C-K(n=10, P＜0.05). Intriguingly, the complex of ginsenoside C-K and lamotrigine reduces seizure intensities, seizure latency was further prolonged(n=10, P＜0.05). CONCLUSION: Ginsenoside C-K can exhibit an antiepileptic effect. The combination of ginsenoside C-K and lamotrigine have synergistic anti-epileptic effect.

Key words: ginsenoside C-K, lamotrigine, epilepsy, seizure activity

CLC Number:

R965.2

ZENG Xiangchang, ZHOU Luping, CHEN Lulu, LUO Wei, LI Chaopeng, GAO Qing, WANG Yaqin, WANG Xintong, HU Kai, SHEN Jie, OUYANG Dongsheng. Effects of ginsenoside C-K on seizure activity in pilocarpine-induced epileptic rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 139-143.

References

［1］Moshe SL, Perucca E, Ryvlin P, et al. Epilepsy: new advances［J］ . Lancet, 2015, 385(9971):884-898.
［2］Schmidt D, Schachter SC. Drug treatment of epilepsy in adults［J］. BMJ, 2014, 348:g254.
［3］Lian XY, Zhang ZZ, Stringer JL. Anticonvulsant activity of ginseng on seizures induced by chemical convulsants［J］. Epilepsia, 2005, 46(1):15-22.
［4］Yang XD, Yang YY, Ouyang DS, et al. A review of biotransformation and pharmacology of ginsenoside compound K［J］. Fitoterapia, 2015, 100:208-220.
［5］Park JS, Shin JA, Jung JS, et al. Anti-inflammatory mechanism of compound K in activated microglia and its neuroprotective effect on experimental stroke in mice ［J］. J Pharmacol Exp Ther, 2012, 341(1):59-67.
［6］Bae MY, Cho JH, Choi IS, et al. Compound K, a metabolite of ginsenosides, facilitates spontaneous GABA release onto CA3 pyramidal neurons［J］. J Neurochem, 2010,114 (4):1085-1096.
［7］Jang S, Ryu JH, Kim DH, et al. Changes of ［3H］MK-801, ［3H］muscimol and ［3H］flunitrazepam binding in rat brain by the prolonged ventricular infusion of transformed ginsenosides［J］. Neurochem Res, 2004,29(12):2257-2266.
［8］Inoue O, Sugiyama E, Hasebe N, et al. Methyl ethyl ketone bloC-Ks status epilepticus induced by lithium-pilocarpine in rats［J］. Br J Pharmacol, 2009,158(3):872-878.
［9］Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure［J］. Electroencephalogr Clin Neurophysiol,1972, 32(3):281-294.
［10］于雷，李成龙，于珊珊. 人参皂苷C-K的研究进展［J］. 生物技术通报,2013(01):31-35.
［11］Lee J, Lee E, Kim D, et al. Studies on absorption, distribution and metabolism of ginseng in humans after oral administration［J］. J Ethnopharmacol, 2009,122(1):143-148.
［12］Lee JH, Kim SR, Bae CS, et al. Protective effect of ginsenosides, active ingredients of Panax ginseng, on kainic acid-induced neurotoxicity in rat hippocampus［J］. Neurosci Lett,2002, 325(2):129-133.
［13］Kim S, Rhim H. Ginsenosides inhibit NMDA receptor-mediated epileptic discharges in cultured hippocampal neurons［J］. Arch Pharm Res, 2004, 27(5):524-530.
［14］Shin EJ, Koh YH, Kim A Y, et al. Ginsenosides attenuate kainic acid-induced synaptosomal oxidative stress via stimulation of adenosine A(2A) receptors in rat hippocampus［J］. Behav Brain Res, 2009,197(1):239-245.
［15］Tohda C, Matsumoto N, Zou K, et al. Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, a metabolite of protopanaxadiol-type saponins［J］. Neuropsychopharmacology, 2004, 29(5):860-868.
［16］Zhang H, Li Z, Zhou Z, et al. Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair［J］. Pharmacol Biochem Behav, 2016, 140:17-26.
［17］Moon J, Park HK, Chu K, et al. The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population［J］. Epilepsia, 2015, 56(10):e161-e167.
［18］Ordonez L, Salgueiro E, Jimeno FJ, et al. Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs［J］. Eur Rev Med Pharmacol Sci,2015,19(14):2732-2737.
［19］Kim JR, Choi J, Kim J, et al. 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol-fortified ginseng extract attenuates the development of atopic dermatitis-like symptoms in NC/Nga mice［J］. J Ethnopharmacol, 2014, 151(1):365-371.
［20］Shin YW, Bae EA, Kim SS, et al. Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis［J］. Int Immunopharmacol, 2005, 5(7-8):1183-1191.

[1]	LI Chenhao, YU Xihua, YAN Wenhao, CHAI Yuxia, LI Yanyan, LI Kun, LI Zeyun. Research progress on the relationship between pediatric epilepsy and vitamin D [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1299-1306.
[2]	DANG Yangbin, LIANG Yuxin, WANG Tiancheng. Research progress on the related treatment of progressive myoclonic epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1184-1194.
[3]	YAN Yukui, HU Jianqin, ZHANG Bing. Clinical study of new and conventional antiepileptic drugs with newly diagnosed partial epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 793-799.
[4]	WANG Ting, HAN Mingming, LI Juan. Effect of dexmedetomidine on muscle relaxant effect of cisatracurium in patients with epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1113-1118.
[5]	TAO Huai, XU Lujiadai, CHEN Xia. Occurrence and clinical treatment of epilepsy associated with gene mutation in voltagegated sodium channel subtypes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 570-577.
[6]	NI Hong, ZHENG Bu-zhen, WANG En, JIN Xiao-ping, MA Chuan-hua, KE Shao-fa, ZHOU Yuan-lin, CHU Zhao-hu. Study of GABAergic neurons electrophysiological changes after levetiracetam intervention in the epileptic mouse hippocampal [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 505-509.
[7]	MAO Jie, JIANG Xiao-chun, XU Shan-shui, WANG Xuan-zhi. The neuroprojective effects of lamotrigine on rat global cerebral ischemic reperfusion damage [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1105-1109.
[8]	TANG Zhi-hua, ZHANG Ke-ying, XIAO Xing-feng. Analysis of the monitoring results and the influencing factors of blood concentration of valproate in patients with epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(9): 1051-1055.
[9]	BAI Xiang-rong, JIANG De-chun, WANG Yu-qin, QI Xiao-lian. Effects of CYP2C19 and CYP2C9 genotype on valproate clearance in patients with epilepsy in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1405-1410.
[10]	ZHANG Shen, WANG Li, LIU Ying. Correlation of lamotrigine concentrations between saliva and serum in children with epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(9): 978-982.
[11]	HONG Gang, ZHANG Jiang-sheng, WANG Lin-hui. Progresses in studies on anti-epileptic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(11): 1201-1209.
[12]	JIANG De-chun, WANG Li, LU Wei. Setting uPpopulation pharmacokinetics/pharmacodynamics model of VPA n children with epilepsy by NONMEM software [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(11): 1279-1289.
[13]	CAO Hui, GUAN Qing-Shan. Efficacy evaluation of topiramate in treatment ofPatients with different types of epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 677-679.
[14]	HE Xi-Mei, HE Xin, ZHANG Er-Huai. Advances of pharmacokinetic studies of topiramate, a new antiepileptic a-gent [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(3): 279-282.